(Reuters) – The U.S. Food and Drug Administration said on Friday it does not expect AstraZeneca’s COVID-19 antibody cocktail Evusheld to provide protection against the Omicron subvariant XBB.1.5. The subvariant …
Topic:
evusheld
-
-
SEOUL – South Korea on Thursday authorised AstraZeneca PLC’s antibody-based therapy for preventing COVID-19 infection in people with a poor immune response, increasing its options as it works to ease …